GSK2374697

a glucagon-like peptide-1 receptor agonist; consists of a human domain antibody fused to exendin-4

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Overweight 10/01/2015 - "Two cohorts of healthy subjects, one normal/overweight and one obese, were randomized to receive GSK2374697 2 mg (n = 8 each) or placebo (n = 4 and n = 2) subcutaneously on days 1, 4 and 7. Samples for plasma endogenous GLP-1 and PYY were collected after breakfast on days -1 and 12. "

1.	Glucagon-Like Peptide 1 (GLP 1)